Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aram... Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. 더 보기
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology PR Newswire TEL AVIV, Israel, Sept. 25, 2024 The paper re-iterates the significant anti-fibrotic effect of Aramchol...
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases PR Newswire TEL AVIV, Israel, Sept. 19, 2024 Aramchol is the most clinically advanced, first-in-class...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.122 | -30.0566572238 | 7.06 | 7.76 | 4.51 | 198346 | 5.92322776 | CS |
4 | 1.678 | 51.472392638 | 3.26 | 23.8 | 2.87 | 8135679 | 12.42099281 | CS |
12 | 1.3368 | 37.1209596801 | 3.6012 | 23.8 | 2.73 | 3161689 | 11.43780592 | CS |
26 | 0.8976 | 22.2156222156 | 4.0404 | 23.8 | 2.73 | 1543516 | 11.15081051 | CS |
52 | -0.582 | -10.5434782609 | 5.52 | 23.8 | 2.73 | 856238 | 10.5151586 | CS |
156 | -482.862 | -98.987699877 | 487.8 | 563.4 | 2.73 | 381067 | 41.46663677 | CS |
260 | -725.862 | -99.3243021346 | 730.8 | 1328.4 | 2.73 | 298732 | 201.70614236 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관